Capricor Therapeutics is trading 6% lower at $8.78, with broad-market risk aversion the likelier immediate pressure.
- A September 23 securities-fraud lawsuit alert reiterated allegations involving Deramiocel and the integrity of clinical data supporting its BLA; the lead-plaintiff deadline is September 28.
- The coverage largely repeats previously reported litigation rather than announcing a new company development. Biotech remains comparatively stronger.